<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="138001">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02084381</url>
  </required_header>
  <id_info>
    <org_study_id>1502</org_study_id>
    <nct_id>NCT02084381</nct_id>
  </id_info>
  <brief_title>PERCI- Medium Cut Off (MCO)</brief_title>
  <acronym>PERCI-MCO</acronym>
  <official_title>Permeability Enhancement to Reduce Chronic Inflammation _ Medium Cut Off (MCO) (Study no 1502)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gambro Dialysatoren GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gambro Dialysatoren GmbH</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The medium cut-off dialysis membrane has been developed to provide a significantly extended
      molecular cut-off compared to conventional high-flux membranes. The medium cut-off membrane
      allows for a high permeability of molecules up to a molecular weight of 45 kDa and has a
      still limited permeability for albumin (68 kDa).

      The main goal of this project is the evaluation of the new, highly porous and selective
      dialysis membrane (MCO-Ci 400) for the treatment of patients with end-stage renal disease in
      hemodialysis mode and to study its potential to improve chronic inflammation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>TNF-alpha mRNA</measure>
    <time_frame>4 weeks treatment time</time_frame>
    <safety_issue>No</safety_issue>
    <description>Significant lower pre- dialytic TNF-α mRNA expression level in circulating peripheral blood mononuclear cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety related events</measure>
    <time_frame>6 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Elimination of inflammatory molecules and uremic toxins from patient's blood</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Kidney Failure</condition>
  <condition>Chronic Inflammation</condition>
  <arm_group>
    <arm_group_label>MCO-Ci 400</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MCO-Ci 400 is the investigational medical product applied in hemodialysis mode</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Revaclear 400</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the standard high flux dialyzer Revaclear 400 is used as  an comparator in hemodialysis mode</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MCO-Ci 400</intervention_name>
    <description>hemodialysis</description>
    <arm_group_label>MCO-Ci 400</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Revaclear 400</intervention_name>
    <description>hemodialysis</description>
    <arm_group_label>Revaclear 400</arm_group_label>
    <other_name>standard high flux dialyzer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CKD5 ( GFR &lt; 15ml/min/ 1.73m2)

          -  Dialysis treatment for ≥ 3 months

          -  Dialysis 3x weekly

          -  Vascular access by fistula or CVC

          -  Age &gt; 18 and &lt; 99 Years

          -  Ability to give written informed consent

        Exclusion Criteria:

          -  Missing informed consent form

          -  current clinically manifested infection or within the last two weeks

          -  current CRP-value &gt; 50mg/L or within the last two weeks

          -  Intake of any medication applied for immunosuppressive purposes

          -  Pregnancy or lactation

          -  Participation in a different interventional study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Girndt, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Martin-Luther-Universität Halle-Wittenberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthias Girndt, Prof. Dr.</last_name>
    <phone>+ 49 (0) 345/5572717</phone>
    <email>matthias.girndt@medizin.uni-halle.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ralf Schindler, Prof. Dr.</last_name>
    <phone>+ 49 (0) 30 450/653132</phone>
    <email>ralf.schindler@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Martin-Luther-Universität Halle-Wittenberg</name>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Girndt, Prof. Dr.</last_name>
      <email>matthias.girndt@medizin.uni-halle.de</email>
    </contact>
    <investigator>
      <last_name>Matthias Girndt, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Schindler, Prof. Dr.</last_name>
      <email>ralf.schindler@charite.de</email>
    </contact>
    <investigator>
      <last_name>Ralf Schindler, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 7, 2014</lastchanged_date>
  <firstreceived_date>February 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CKD5, dialysis, high porous membranes</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
